In the following series, Jerry Cahill - BEF CF Ambassador, will answer viewer submitted questions about health, wellness, fitness, and cystic fibrosis in short-format videos....
In Jerry Cahill’s latest video podcast, Jenn Caruso shares her story of being a mother to a son with cystic fibrosis. She imparts the importance of having a great support group, of allowing her son to take ownership of his care (even when it’s difficult),...
SOURCE: VERTEX
Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis
Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with...
The Boomer Esiason Foundation has awarded prestigious "Sacks for CF" academic scholarships to 30 outstanding students with cystic fibrosis.
Through the NFL season, longtime BEF partner Abbvie makes a donation to the BEF Sacks for CF scholarship program for every quarterback sack recorded during NFL Monday...
Lea slid into my DMs about two and a half years ago asking if I’d be willing to help her with a video she was making for Tiffany Rich’s transplant recovery. Lea’s best friend was in a dire situation and all she wanted to do...
The U.S. Food and Drug Administration (FDA) approved SYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to treat cystic fibrosis (CF) in people ages 12 years and older who have two copies of the F508del mutation or one mutation that is responsive to SYMDEKO. SYMDEKO is Vertex’s third CF...
The Boomer Esiason Foundation has awarded prestigious "Sacks for CF" academic scholarships to 30 outstanding students with cystic fibrosis.Through the NFL season, longtime BEF partner Abbvie makes a donation to the BEF Sacks for CF scholarship program for every quarterback sack recorded during NFL Monday...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Development...
Alcresta Therapeutics Receives 510(k) Clearance For Use of RELiZORB® in ChildrenRELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children Suffering from Fat MalabsorptionJuly 20, 2017 08:30 AM Eastern Daylight TimeWARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc., dedicated to developing...
